Filing search / Inhibrx Biosciences, Inc. / "Safety" / Page 4

8-K

syi8jqpganppjd31e5k1

21 Jun 21

Entry into a Material Definitive Agreement

4:05pm

8-K

EX-99.2

y5jkyxyqpdpg

21 Jun 21

Entry into a Material Definitive Agreement

4:05pm

8-K

EX-99.1

r14zsm

21 Jun 21

Entry into a Material Definitive Agreement

4:05pm

8-K

EX-99.2

b8l9 27nq

12 Mar 21

Results of Operations and Financial Condition

8:55am

8-K

EX-99.1

3ussx5xo

12 Mar 21

Results of Operations and Financial Condition

8:55am

10-K

j21uwtl8 i9sfk7

12 Mar 21

Annual report

8:46am

8-K

EX-99.1

doambe

13 Jan 21

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

9:03am

8-K

EX-99.2

wxo nd6a6vavj9g

5 Jan 21

Inhibrx Announces Phase 1 Dose Escalation Results of

12:00am

8-K

EX-99.1

5d6wyn80riiwlpnr9x

5 Jan 21

Inhibrx Announces Phase 1 Dose Escalation Results of

12:00am

10-Q

8zcuhp9

13 Nov 20

Quarterly report

4:09pm

8-K

c8sthfaol c4z6h

12 Nov 20

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

6:07am

8-K

EX-99.1

9618xiw goz7z5as

12 Nov 20

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

6:07am

8-K

EX-99.2

f1u4a ddfon7d0li1sc

12 Nov 20

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

6:07am

8-K

EX-99.1

tjvw88n0thshbacq1

11 Sep 20

Regulation FD Disclosure

4:24pm

8-K

EX-3.2

2prn jsyvxb1

21 Aug 20

Unregistered Sales of Equity Securities

4:19pm

424B4

tyl 6z5pei8uvto

19 Aug 20

Prospectus supplement with pricing info

5:21pm